Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Calcium channel blockers (CCBs) block calcium channels in cardiac and smooth muscle cells, inhibiting calcium ion influx. This causes vasodilation and reduces myocardial oxygen demand, relieving angina symptoms. CCBs include dihydropyridines like nifedipine, phenylalkylamines like verapamil, and benzothiazepines like diltiazem, all used to manage ischemic heart disease.

Calcium channel blockers comprise three classes: dihydropyridines such as nifedipine, phenylalkylamines such as verapamil, and benzothiazepines such as diltiazem. All undergo extensive metabolism when administered orally. Verapamil and diltiazem can also be given intravenously, offering flexible dosing options for acute and chronic angina management.

Ranolazine is a sodium-channel blocker that inhibits late-phase sodium current during cardiac repolarization, preventing calcium entry via the sodium-calcium exchanger. This reduces intracellular sodium and calcium levels, relaxing cardiac muscle and improving coronary blood flow through a distinct mechanism from CCBs that block calcium channels directly.

Common side effects of calcium channel blockers include headache, dizziness, and peripheral edema. These effects result from vasodilation and fluid retention in tissues. Most patients tolerate CCBs well, though side effects may require dose adjustment or switching to alternative antianginal medications in some clinical cases.

Ranolazine is well absorbed when taken orally and is primarily metabolized by CYP3A enzymes in the liver. This metabolic pathway is important for drug interactions, as inhibitors or inducers of CYP3A can affect ranolazine levels and efficacy in treating angina pectoris symptoms.

Common side effects of ranolazine include dizziness, headache, constipation, and nausea. These effects are generally mild and manageable with continued use. Ranolazine offers an alternative for angina patients who cannot tolerate or respond adequately to other antianginal agents like calcium channel blockers.

Verapamil and diltiazem can be given orally or intravenously, unlike dihydropyridines, providing treatment flexibility. Intravenous administration allows rapid onset for acute angina episodes, while oral forms provide maintenance therapy. This dual-route capability makes them versatile antianginal agents in both acute and chronic management scenarios.